Abstract
A new compound, 8[[3-[4-(2-[(11)C]methoxyphenyl)piperazin-1-yl]-2-hydroxypropyl]oxy]thiochroman was labeled via O-methylation with [(11)C]methyl iodide in good yield and specific activity. Original biological evaluations included (i) the study in anesthetized rat with a beta-sensitive intracerebral probe (beta-Microprobe), allowing to measure locally the kinetic of the new PET ligand, and (ii) a PET-scan on a conditioned cat maintained awake during the acquisition. In both in vivo techniques, the new ligand did not reveal any specific binding in hippocampus indicating that this radiotracer is not suitable for mapping 5HT(1A) receptors using positron emission tomography.
Publication types
-
Comparative Study
-
Evaluation Study
-
Validation Study
MeSH terms
-
Anesthesia
-
Animals
-
Brain / diagnostic imaging*
-
Brain / metabolism*
-
Cats
-
Isotope Labeling / methods
-
Male
-
Metabolic Clearance Rate
-
Piperazines / chemical synthesis
-
Piperazines / pharmacokinetics*
-
Radionuclide Imaging
-
Radiopharmaceuticals / chemical synthesis
-
Radiopharmaceuticals / pharmacokinetics
-
Rats
-
Rats, Sprague-Dawley
-
Receptors, Presynaptic / antagonists & inhibitors
-
Receptors, Presynaptic / metabolism
-
Receptors, Serotonin, 5-HT1 / metabolism*
-
Serotonin 5-HT1 Receptor Antagonists*
-
Thiophenes / chemical synthesis
-
Thiophenes / pharmacokinetics*
-
Tissue Distribution
-
Unconsciousness
-
Wakefulness / physiology
Substances
-
8-((3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-hydroxypropyl)oxy)thiochroman
-
Piperazines
-
Radiopharmaceuticals
-
Receptors, Presynaptic
-
Receptors, Serotonin, 5-HT1
-
Serotonin 5-HT1 Receptor Antagonists
-
Thiophenes